Supplier News Breaks Archives
NasalCEASE program supports bleeding disorder research
June 20th, 2012
MENDON, N.Y. – Nosebleed treatment brand NasalCEASE has introduced a marketing program that stands to donate thousands of dollars to support research for hereditary hemorrhagic telangiectasia (HHT) and hemophilia as well as anticoagulation therapy education.
NasalCEASE maker Catalina Healthcare said Wednesday that under the "NasalCEASE Gives Back" program it will donate $2 for each box of NasalCEASE purchased between June 1 and Nov. 30.
Consumers buying NasalCEASE will designate one of three organizations where the donation should be directed: the HHT Foundation, the Hemophilia Foundation or the Anticoagulation Forum. And for every three boxes of NasalCEASE purchased, the consumer receives one free box of NasalCEASE. Consumers can get further savings by using NasalCEASE $1 off per box coupons.
"NasalCEASE is a critical product in the lives of so many people with HHT, hemophilia, anticoagulation concerns and bleeding caused by other issues," stated Bruce Ford, president of Catalina Healthcare. "Beyond providing unique product technology that ensures bleeding is quickly and easily stopped, NasalCEASE now wants to give back and provide funds to help support research and education associated with these chronic bleeding issues."
According to Catalina, NasalCEASE is a safe, natural-based bio-polymer: 100% calcium alginate, an active coagulant that works quickly to stop bleeding, without side effects or contraindications with other medications. As soon as NasalCEASE comes in contact with blood, calcium is released, accelerating coagulation and blood absorption. Calcium alginate can absorb up to 20 times its weight in blood, the company noted, adding that the product also stops bleeding from everyday cuts or puncture wounds, such as shaving cuts, cuts around the home, and puncture wounds from needles or other medical devices.
Catalina said most cuts and nosebleeds can be treated with just one NasalCEASE packing. One box of the product, found in the first aid aisles of over 30,000 pharmacies nationwide, contains five sterile packings.
The company said NasalCEASE is the product of choice for the nation's 70,000 HHT sufferers — 94% of whom suffer from frequent nosebleeds — and is ideal for people taking prescription blood thinners and/or a daily baby aspirin or people with blood clotting disorders, such as hemophilia or von Willebrand disease.
"The HHT Foundation is pleased to be one of the beneficiaries of 'NasalCEASE Gives Back,' " commented Mary Leigh Krock, manager of member services for HHT International. "We appreciate the generous support of Catalina Healthcare and look forward to working with them to communicate this program to the many people with HHT."